1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Medigene AG

Medigene AG

MDG1.F
Medigene AGundefined flagFrankfurt Stock Exchange
0.02
EUR
+0.00
- -
253,487.00Market Cap
Medigene AG
MDG1.F
(Frankfurt Stock Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
8.85
0.62
0.48
0.95
1.29
1.5
2.14
0.77
0.93
0.78
0.62
0.82
0.62
0.81
2.42
0.47
0.82
Revenue per Share
-6.88
-4.87
-3.71
1.29
-2.02
-2.03
-0.9
-1.47
-0.9
-1.41
-1.7
-1.54
-2.23
-0.77
-0.64
-1.25
-1.18
Basic EPS, GAAP
-6.19
-4.28
-2.44
1.32
-1.39
-2.44
-1.5
-1.35
-0.52
-1.98
-0.9
-1.38
-1.95
-0.84
0.85
-1.22
-0.87
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-57.91
-62.07
-61.5
-59.36
-61.39
-66.48
-52.72
-39.11
-32.88
-31.74
-30.36
-30.8
-33.03
-33.8
-34.44
-35.69
-30.8
Book Value per Share
5.65
2.24
1.39
3.69
2.99
1.4
1.66
6.13
5
5.05
5.38
3.57
1.66
1.14
2.11
0.87
3.57
Tangible Book Value per Share
4
5
5
5
5
5
6
9
11
11
12
13
13
13
13
13
13
Basic Weighted Avg Shares
40
3
2
5
6
8
14
7
10
9
8
11
8
10
31
6
11
Sales/Revenue/Turnover
-63.8
-908.19
-1,203.93
-336.21
-163.49
-109.08
-20.9
-153.33
-135.56
-178.81
-229.88
-189.63
-291.59
-95.43
-27.93
-267.63
-189.63
Operating Margin (%)
7
1
10
5
1
1
1
1
1
1
2
2
6
3
22
1
- -
Depreciation Expense
-31
-22
-18
6
-10
-10
-6
-13
-9
-16
-21
-20
-29
-10
-8
-16
-15
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-77.74
-788.58
-779.62
134.9
-156.89
-135.43
-41.77
-190.94
-97.36
-180.02
-273.74
-187.75
-360.85
-95.41
-26.66
-268.1
-143.75
Profit Margin (%)
21
7
1
13
20
11
17
50
54
55
49
48
23
16
30
11
48
Working Capital
- -
- -
- -
- -
- -
10
- -
1
- -
1
1
5
4
3
3
2
5
LT Debt
65
52
41
48
44
36
49
90
88
93
103
82
53
45
37
21
82
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'19
Sep'19
Dec'19
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
5
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
183
151
98

Working Capital

FRC

•

in mil. unless spec.
Jun'19
Sep'19
Dec'19
Total Current Assets
70
66
58
Cash, Cash Equivalents & STI
65
61
55
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
12
13
10
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.11%
-26.39%
-43.1%
Free Cash Flow
-19.38%
-80.02%
-243.89%
Net Income, GAAP
20.69%
10.18%
94.2%
Sales/Revenue/Turnover
21.36%
32.22%
-80.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
2
- -
- -
- -
31
2023
2
- -
- -
- -
6
2024
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.18
- -
- -
- -
-0.64
2023
-0.33
- -
- -
- -
-1.25
2024
-0.3
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Passage Bio, Inc. (PASG)
SanBio Company Limited (SNBIF)
Syndax Pharmaceuticals, Inc. (SNDX)
Dimerix Limited (DXB.AX)
Lunai Bioworks Inc. (RENB)
Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
Business
Medigene AG, an immuno-oncology platform company, specializes in the discovery and development of T cell receptor (TCR) engineered therapies for cancer. Through its End-to-End TCR platform, Medigene focuses on identifying and optimizing 3S TCRs (sensitive, specific, and safe) and develops multiple modalities including autologous and allogeneic TCR-T therapies, TCR-guided cell therapies, and TCR-TCE programs in collaboration with partners. The company’s lead programs include MDG1015, a TCR-T therapy targeting solid tumors, and its broader pipeline spans off-the-shelf modalities and combination approaches designed to enhance safety and efficacy. Medigene operates primarily in Planegg/Martinsried, Germany, with development activities and partnerships that extend to global biotechnology and pharmaceutical markets. Founded in 1994, Medigene maintains its headquarters in Planegg/Martinsried and advances its research through collaborations, licensing agreements, and strategic partnerships that broaden its TCR platform applications across oncology indications. The company emphasizes a diversified strategy that integrates internal product development with external collaborations to expand its TCR-T and TCR-TCE portfolios, while pursuing financial and operational measures to sustain clinical and preclinical activities. In addition to its in-house programs, Medigene engages with strategic partners to accelerate product development, clinical testing, and potential commercialization in major markets, reinforcing its position as a specialized immuno-oncology developer.